General Atlantic L.P. Sells 3,564,103 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

General Atlantic L.P. lowered its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 36.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,117,715 shares of the company’s stock after selling 3,564,103 shares during the period. Centessa Pharmaceuticals accounts for approximately 5.3% of General Atlantic L.P.’s portfolio, making the stock its 8th largest position. General Atlantic L.P. owned 4.55% of Centessa Pharmaceuticals worth $153,004,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Foresite Capital Management VI LLC lifted its position in shares of Centessa Pharmaceuticals by 4.8% in the 3rd quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after purchasing an additional 60,640 shares during the period. Eagle Health Investments LP acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $2,500,000. SG Americas Securities LLC lifted its position in shares of Centessa Pharmaceuticals by 1,017.7% in the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock worth $6,593,000 after purchasing an additional 240,039 shares during the period. Royce & Associates LP acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $5,999,000. Finally, Cinctive Capital Management LP acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $2,246,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. B. Riley Financial downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a research report on Monday, April 13th. Finally, Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $39.75 on Wednesday. The firm has a market capitalization of $6.15 billion, a PE ratio of -22.21 and a beta of 1.11. The firm has a fifty day simple moving average of $39.65 and a two-hundred day simple moving average of $31.04. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $12.30 and a 12 month high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.